Registry of Lobbyists

Registration - In-house Corporation

Hoffmann-La Roche Limited / BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Registration Information

In-house Corporation name: Hoffmann-La Roche Limited
Previous in-house corporation names
Responsible Officer Name: BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER 
Responsible Officer Change History
Initial registration start date: 2001-01-18
Registration status: Active
Registration Number: 952745-64

Associated Communications

Total Number of Communication Reports: 450

Monthly communication reports in the last 6 months: 24

Version 7 of 64 (2007-05-31 to 2007-12-20)

Version 7 of 64 (2007-05-31 to 2007-12-20) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: Hoffmann-La Roche Limited
2455 Meadowpine Blvd.
Mississauga, ON  L5N 6L7
Canada
Telephone number: 905-542-5555
Fax number: 905-542-7130  
Responsible officer name and position during the period of this registration: RONNIE MILLER, PRESIDENT AND CEO  
Description of activities: Hoffmann-La Roche Limited deals with the healthcare system in the diagnosis, treatment and management of acute and long-term disease and supports leading research and development - including clinical research, clinical trials and genetic research.
 
The client is a subsidiary of the following parent companies: F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basle
Switzerland

Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Corporation

Name: Linnea Doyle
Position title: Director of Market Access
Public offices held: No
 
Name: Brigitte Nolet
Position title: Director, Federal Health Policy and Government Relations
Public offices held: Yes
 
Name: Jamie Slater
Position title: Product Manager
Public offices held: No
 
Name: Ilona Torontali
Position title: Vice President, Public Affairs
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Aboriginal Affairs and Northern Development Canada, Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Canadian Space Agency (CSA), Canadian Transportation Agency (CTA), Citizenship and Immigration Canada, Competition Tribunal (CT), Correctional Service of Canada (CSC), Environment Canada, Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Human Resources Development Canada (HRDC), Industry Canada, Justice Canada (JC), Members of the House of Commons, National Defence (DND), National Research Council (NRC), Natural Resources Canada (NRCan), Natural Sciences and Engineering Research Council (NSERC), Office of the Auditor General, Office of the Information and Privacy Commissioner (OIPC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Safety and Emergency Preparedness Canada (PSEPC), Public Service Commission of Canada (PSC), Public Works and Government Services Canada, Revenue Canada (RC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Service Canada (ServCan), Solicitor General Canada (SGC), Statistics Canada (StatCan), Transport Canada (TC), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC), Western Economic Diversification Canada (WD)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Aboriginal Affairs, Agriculture, Constitutional Issues, Consumer Issues, Defence, Education, Employment and Training, Energy, Environment, Financial Institutions, Fisheries, Forestry, Government Procurement, Health, Immigration, Industry, Infrastructure, Intellectual Property, Internal Trade, International Relations, International Trade, Justice and Law Enforcement, Labour, Regional Development, Science and Technology, Small Business, Sports, Taxation and Finance, Transportation
 
Subject Matter: Retrospective: Industry Canada: political/bureaucrat - Science and Technology Strategy, Patented Medicines (PM) Notice of Compliance (NOC) regulations, Budget, issues affecting health and pharmaceutical industries, Pharma Partnering, international aid programs and biotechnology. Health Canada: Science and Technology Strategy, PM (NOC) regulations, data protection, pandemic planning, international aid programs.
Subject Matter: Prospective: Treasury Board: Smart Regulations, pandemic planning Industry Canada: Science and Technology Strategy, PM (NOC) regulations, Patent Act, pharmaceutical and biotechnology R&D issues, smart regulations, patent policy, lifesciences industry, biosimilars, international aid programs, and pharma partnering.Health Canada: drug safety, data protection regulations, innovation issues, drug approval, counterfeit drugs, pandemic planning, international aid programs, and national pharmaceutical strategy. Foreign Affairs/Trade: ongoing international issues, patent issues, access and benefit sharing issues, international aid programs. Finance: Budget/budget update CIDA: international aid programs
 

Details Regarding the Identified Subject Matter

Categories Description
Policy or Program access and benefit sharing issues
Policy or Program Canada's Access to Medicines Regime
Regulation data protection regulations
Bill or Resolution, Policy or Program Food and Drugs Act
Policy or Program international aid programs
Policy or Program international pharmaceutical issues
Policy or Program lifesciences trends
Policy or Program national pharmaceutical strategy
Policy or Program pandemic planning
Bill or Resolution Patent Act
Policy or Program Patented Medicine Prices Review Board Pricing Guidelines
Policy or Program patent policy
Policy or Program pharmaceutical and biotechnology R&D issues
Regulation PM (NOC) regulations
Policy or Program Science and Technology Strategy
Policy or Program smart regulations
Regulation, Policy or Program Subsequent Entry Biologics




Date Modified: